HopeStage
Back to all studies
CompletedNCT00226343

Divalproex compared with placebo for depression in bipolarity

About this title

Depakote-ER for Depressive and Bipolar Depression

Read the official source — NCT00226343
Medication studyAges 18–65
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2003
Recruitment status
Completed
Enrollment listed in the registry
25
Sponsor
Cambridge Health Alliance
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Not clearly listed
Age range
From 18 Years to 65 Years
Official registry ID
NCT00226343
Official title
Show the full official title

Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Cambridge Health Alliance.

Did this study involve medication?

Yes. The study involved medication, including Depakote-ER.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies